In sum, anti-NGF antibodies are a promising therapeutic option in the treatment of OA, as they improve pain and function in patients; however, despite these benefits, meta-analyses of clinical trial data found that these agents increased the risk of neurological adverse effects (paresthesia, hypoesthesia, and peripheral neuropathy), being greater in patients treated with tanezumab than in patients treated with placebo and NSAIDs. Here, NGF is linked to peripheral neuropathy.